MET and glioblastoma: In clinical samples comparing primary and recurrent GBM, varying expression levels of targets such as ALK, PDGFRβ, PDGFRA, MET, FGFR1, FGFR2, and FGFR3 have been observed, indicating significant heterogeneity throughout the disease’s progression.